AstraZeneca lung cancer drug given green light in US
by Julia Kollewe from on (#TGH1)
FDA approval of Tagrisso offers major boost for British company, seeking to release six new cancer medicines by 2020
A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.
AZD9291, which will be sold as Tagrisso, is for advanced non-small-cell lung cancer, the most common form of lung cancer. Tagrisso targets a genetic mutation, known as T790M, that helps tumours evade current lung cancer pills. The drug will be made available to patients in the US as soon as possible and its price will be "comparable to other oral cancer therapies," a spokeswoman said. AstraZeneca will reveal the price early next week.
Continue reading...